Biopharma | May 08, 2026
Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore
Among the growth drivers are biosimilars business, operational efficiencies, and integration of biosimilars and generics operations
Among the growth drivers are biosimilars business, operational efficiencies, and integration of biosimilars and generics operations
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
US business grew by +12.8% YoY
Subscribe To Our Newsletter & Stay Updated
